Scorpius Holdings Launches Scorpius Ventures to Support U.S. Biotech Innovation through Flexible Equity-Based Onshoring Model
| SCPX Stock | 0.55 0.20 57.14% |
Slightly above 59% of all Scorpius Holdings' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Scorpius Holdings suggests that some traders are interested. Scorpius Holdings' investing sentiment can be driven by a variety of factors including economic data, Scorpius Holdings' earnings reports, geopolitical events, and overall market trends.
Scorpius |
New business unit offers services for promising biotech companies through combined fee-for-service and equity-based model, fostering partnerships that...
Read at globenewswire.com
 |
Scorpius Holdings Fundamental Analysis
We analyze Scorpius Holdings' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scorpius Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scorpius Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Scorpius Holdings is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Scorpius Holdings Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Scorpius Holdings stock to make a market-neutral strategy. Peer analysis of Scorpius Holdings could also be used in its relative valuation, which is a method of valuing Scorpius Holdings by comparing valuation metrics with similar companies.
Peers
Scorpius Holdings Related Equities
| ZVSA | ZyVersa Therapeutics | 13.76 | ||||
| SONN | Sonnet Biotherapeutics | 9.37 | ||||
| ICU | LMF Acquisition | 7.69 | ||||
| QNRX | Quoin Pharmaceuticals | 4.48 | ||||
| MNPR | Monopar Therapeutics | 3.42 | ||||
| CMND | Clearmind Medicine | 2.76 | ||||
| GNLX | Genelux Common | 2.12 | ||||
| DYAI | Dyadic International | 0.57 | ||||
| CING | Cingulate | 0.98 | ||||
| REVB | Revelation Biosciences | 1.52 |
Additional Tools for Scorpius Stock Analysis
When running Scorpius Holdings' price analysis, check to measure Scorpius Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scorpius Holdings is operating at the current time. Most of Scorpius Holdings' value examination focuses on studying past and present price action to predict the probability of Scorpius Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scorpius Holdings' price. Additionally, you may evaluate how the addition of Scorpius Holdings to your portfolios can decrease your overall portfolio volatility.